logo
Sign In
  1. Home
  2. Indications
  3. Unresectable Melanoma

Medications for Unresectable Melanoma

FiltersReset Filters
5 results

  • cotellic

    (COBIMETINIB)
    Medication Details
    Genentech, Inc.
    Usage: COTELLIC® is indicated for adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations, in combination with vemurafenib. It is also indicated as a single agent for the treatment of adult patients with histiocytic neoplasms.
    Medication Details
    Drug Interactions

  • mektovi

    (BINIMETINIB)
    Medication Details
    Array BioPharma Inc.
    Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.
    Medication Details
    Drug Interactions

  • opdivo

    (nivolumab)
    Medication Details
    E.R. Squibb & Sons, L.L.C.
    Usage: OPDIVO is indicated for the treatment of various cancers, including unresectable/metastatic melanoma, neoadjuvant and adjuvant non-small cell lung cancer, metastatic non-small cell lung cancer, malignant pleural mesothelioma, advanced renal cell carcinoma, classical Hodgkin lymphoma, and others. It is used in different combinations and settings based on the cancer type.
    Medication Details
    Drug Interactions

  • yervoy

    (ipilimumab)
    Medication Details
    E.R. Squibb & Sons, L.L.C.
    Usage: YERVOY is indicated for treating unresectable or metastatic melanoma, adjuvant melanoma post-resection, advanced renal cell carcinoma, microsatellite instability-high colorectal cancer, hepatocellular carcinoma, metastatic non-small cell lung cancer, malignant pleural mesothelioma, and unresectable esophageal cancer, often in combination with nivolumab.
    Medication Details
    Drug Interactions

  • zelboraf

    (Vemurafenib)
    Medication Details
    Genentech, Inc.
    Usage: ZELBORAF® is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation and for Erdheim-Chester Disease (ECD) with the same mutation. It is not suitable for patients with wild-type BRAF melanoma.
    Medication Details
    Drug Interactions
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutCareersContact UsSecurity
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.